Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.

METHODS: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).

RESULTS: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).

CONCLUSIONS: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.

OriginalsprogEngelsk
TidsskriftCancer Investigation
Vol/bind36
Udgave nummer9-10
Sider (fra-til)512-519
Antal sider8
ISSN0735-7907
DOI
StatusUdgivet - 2018

ID: 56497380